Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene announced the successful completion of the first-in-human Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in combination with Nivolumab for advanced solid tumors. The open-label study enrolled 11 patients who had progressed on prior anti-PD-1 therapy. The trial met its primary endpoint of favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary efficacy signals included one partial response and five patients achieving stable disease beyond the 16-week combination period.
Key figures
- Drug Name
- BMC128 (now LS-LBP-002)
- Phase Of Trial
- Phase 1
- Partial responses
- 1
- Patients enrolled
- 11
- Patients on maintenance
- 2
- Stable disease patients
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.